Leroy

Leroy Chiao is the CEO and co-founder of OneOrbit LLC, a motivational, training and education company. He served as a NASA astronaut from 1990-2005 and flew four missions into space aboard three space shuttles and once as the co-pilot of a Russian Soyuz spacecraft to the International Space Station. On that flight, he served as the commander of Expedition 10, a 6.5-month mission. Chiao has performed six spacewalks, in both U.S. and Russian spacesuits, and has logged 229 days in space. Chiao's professional background is deeply rooted in engineering; he studied the subject as a university sophomore and went on to work for several years before joining NASA. As an astronaut, Chiao was involved in various missions and spacewalks, demonstrating his expertise in the field of space exploration. After retiring from NASA, Chiao turned his attention to education through his company OneOrbit LLC. The organization focuses on motivational speaking, training and education for individuals looking to improve their skills and achieve their goals. In addition to his work with OneOrbit LLC, Chiao has contributed articles on space exploration and film reviews to Space.com, showcasing his knowledge in the field of space technology and offering insights into the industry.

Biography:  https://www.yahoo.com/news/former-astronaut-leroy-chiao-turned-173100856.html

92%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

95%

Examples:

  • The Shield test has been available since 2022,

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

95%

Examples:

  • The self-pay price of the FDA-approved version of Shield was not provided by Guardant

Deceptions

80%

Examples:

  • The test, known as Shield, has been available in the U.S. since 2022 for use by laboratories, but is not covered under Medicare.

Recent Articles

Two New FDA-Approved Blood Tests for Colorectal Cancer: Shield by Guardant Health and Exact Sciences' FIT Test - Comparison, Effectiveness, and Implications

Two New FDA-Approved Blood Tests for Colorectal Cancer: Shield by Guardant Health and Exact Sciences' FIT Test - Comparison, Effectiveness, and Implications

Broke On: Monday, 29 July 2024 Two new blood tests, Shield from Guardant Health and Exact Sciences' FIT test, have been approved by the FDA for colorectal cancer screening. Shield detected 83% of colorectal cancers but is less effective in identifying precancerous polyps. The FIT test has a higher sensitivity rate of 92.3%, making it more effective at detecting cancers, but may require additional testing for confirmation. These tests offer alternatives to colonoscopies, which are invasive and require bowel preparation.